PROJECT SUMMARY Development or repurposing of drugs for SARS-CoV-2 that causes COVID-19 is an active area of research, but not much effort is being spent on developing platforms to identify mutations that may merge to the inhibitors or neutralizing agents for these targets. Given the widespread prevalence of SARS-CoV-2 and potential abuse of developed therapeutic agents, the emergence of such escape mutants is likely. We will develop a virus-free platform to identify and validate escape mutants for therapeutic agents in the pipeline for SARS-CoV-2.